NuCana plc
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsNuCana plc is a clinical-stage pharmaceutical company developing chemotherapy agents called ProTides, listed on Nasdaq under NCNA.
What they do
NuCana plc is a pharmaceutical preparations company incorporated in England and Wales with principal offices in Edinburgh, United Kingdom. The company is developing a portfolio of chemotherapy agents based on its ProTide technology, which is designed to deliver improved versions of existing chemotherapy drugs. Its American Depositary Shares, each representing five thousand ordinary shares, trade on The Nasdaq Stock Market LLC under the symbol NCNA.
Revenue drivers
- ProTide product candidates — The company's business centers on its pipeline of ProTide chemotherapy agents; as a clinical-stage company, it does not currently generate product revenue.
Recent performance
The filing provided is the cover page and table of contents of the company's annual report on Form 20-F for the fiscal year ended December 31, 2025, filed March 19, 2026. The filing confirms the company is a non-accelerated filer and an emerging growth company that reports under U.S. GAAP. No revenue, net loss, or other financial results were included in the excerpts provided, so specific performance figures cannot be reported.
Strategy
The filing excerpts do not contain management's discussion of strategy, so no strategic priorities can be described from the source material. The table of contents shows the 20-F includes sections on operating and financial review, liquidity and capital resources, and research and development, but the content of those sections was not provided.
Risks
- Clinical-stage company — As a company whose pipeline consists of product candidates, it has no approved products or product revenue as described in the filing excerpts.
- Foreign private issuer — NuCana reports as a foreign private issuer incorporated in England and Wales, which affects its reporting and governance obligations.
- Nasdaq listing — Its ADSs trade on Nasdaq under NCNA and are subject to that exchange's continued listing requirements.
- Emerging growth company status — The filing indicates the company is an emerging growth company, a status that carries scaled disclosure and reporting requirements.
Outlook
The provided excerpts do not include management's forward-looking commentary or guidance. The Form 20-F table of contents shows sections on trend information and liquidity, but their content was not part of the excerpts.